Patients' access to drugs with rebates in Switzerland - Empirical analysis and policy implications for drug pricing in Europe

• Главные авторы: David L Carl, BA (Автор), Kerstin N Vokinger, MD, JD, PhD, LLM (Автор)
• Формат: ‌
• Опубликовано: Elsevier, 2021-04-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Background: Many European countries introduced (confidential) rebates in the past years. Authorities and manufacturers argue that this strategy allows reduction of spending on high-cost drugs, and quick access of innovative drugs. We evaluated these arguments using Switzerland as an example, one of...